Before Hologic’s 3D digital mammography system can become a commercial product on the U.S. market, the company must develop a program to train physicians on how to interpret this new kind of mammogram.
Before Hologic’s 3D digital mammography system can become a commercial product on the U.S. market, the company must develop a program to train physicians on how to interpret this new kind of mammogram.
“It is digital mammography, so it’s nothing that new,” said Arthur Friedman, a Hologic senior vice president in charge of regulatory, clinical, and quality issues. “But there are slight differences.”
When interpreting conventional digital mammography, radiologists mentally “triangulate” 2D images, said Dr. Emily Conant, a professor of radiology at the University of Pennsylvania Medical Center in Philadelphia.
“Tomosynthesis allows us to scroll through the breast to see in-plane imaging at various depths,” Conant said. “With this, we can find lesions that potentially we couldn’t see before, or explain away pseudolesions that would otherwise lead to false positives.”
But lesions seen in 3D look different, she said, than those in 2D. That’s where the vendor training program will come in. Hologic has already done two studies looking into how physicians should be trained to interpret these images, Friedman said.
September’s unanimous vote by the FDA’s Radiological Devices Panel in favor of Selenia Dimensions paved the way for the system to be commercialized in the U.S. The training program-and only a few “housekeeping” issues-remain to be resolved, Friedman said. If all goes according to plan, Hologic’s 3D digital mammography system could be on the U.S. market within six months.
Early adopters will have a familiar base to work from. Breast tomosynthesis will complement, not replace, 2D digital mammography. Hologic’s regulatory submission to the FDA is based on data from multicenter clinical trials indicating that cancer is easier to spot when interpreting a combination of 3D and 2D views than when looking at 2D images alone. The combination also promises to reduce recall rates.
Mammography and Breast MRI: Is it Time to Evaluate Strategies as Opposed to Modalities?
July 5th 2024The combination of mammography with breast MRI within 90 days had a 96.2 percent sensitivity in comparison to 48.1 percent for mammography and 79.7 percent for breast MRI performed within 91 to 270 days after index mammography, according to newly published research.
ACR Collaborative Model Leads to 35 Percent Improvement with Mammography Positioning Criteria
July 1st 2024Noting significant variation with facilities for achieving passing criteria for mammography positioning, researchers found that structured interventions, ranging from weekly auditing of images taken by technologists to mechanisms for feedback from radiologists to technologists, led to significant improvements in a multicenter study.